NCT06078982 2023-10-12Posterior-line Treatment With Disitamab Vedotin Plus PD-1 in Advanced HER2-low Expressing Gastric CancerShanghai East HospitalPhase 1 Unknown39 enrolled
NCT05627414 2022-11-25Conversion Therapy of Disitamab Vedotin Combined With Sintilimab and S-1 in HER2 Overexpression Gastric CancerTianjin Medical University Cancer Institute and HospitalPhase 2 Unknown30 enrolled